Bitfount | Bitfount v12.73.0 | Booth 28 
https://www.bitfount.com/ 

Bitfount is an on-premises AI platform that enables sponsors, CROs, sites, and algorithm developers to work together seamlessly on clinical research and clinical trials. The Bitfount platform uses advanced AI models for mining and analyzing medical imaging and medical EHR data in hospitals and clinics to find eligible patients for efficacy studies, observational studies, and much more, accelerating timelines and cutting costs. Crucially, no data is ever shared or seen by any third parties. The no-code desktop application also provides additional capabilities for AI model training and evaluation, all while preserving the privacy of data. In the latest release, the Bitfount platform has a capability called 'In-site Insights' which allows sites to run on-premises AI analysis on their site data and get reports about their patient populations, estimated biomarker growth rates, etc. This helps the sites better select the trials they should participate in. For sponsors, it automates the site selection and feasibility. 

Citeline | Citeline PatientMatch version 1 | Booth 27 
https://www.citeline.com/en/products-services/patient-engagement-and-recruitment/patientmatch 

Citeline PatientMatch delivers custom-timed alerts to investigators and site staff when patients who match your specified protocol receive lab or biomarker results that could make them eligible for your study. Empower your principal investigators to optimize their time and concentrate on ideal trial participants, streamlining recruitment processes before the window of opportunity closes. 

CluePoints | Intelligent Query Detection (IQD) | Booth 12 
https://cluepoints.com/what-we-do/intelligent-query-detection-iqd/ 

Intelligent Query Detection (IQD) addresses the three main pain points of query detection – manual listing review and creation, and query creation. Traditional manual reviews are cognitively exhausting, inefficient, and prone to human error. As data flows in, listings must be reviewed line by line for discrepancies in Excel or SAS, with progress and changes tracked manually. Once issues are found, data managers must log into the EDC, locate each data point, and manually draft queries. These queries vary in style and often require multiple conversations with clinical sites for resolution. This introduces variability and inefficiency and can hinder query resolution. Creating study listings is also resource intensive. The data manager outlines the required checks, and the programmer maps listing columns to dataset variables, often involving significant back-and-forth to clarify requirements, write and test code, and complete UAT. IQD addresses these pain points with a modern, AI-driven approach which automates discrepancy review, generates suggested queries and eliminates manual setup. Instead of data managers combing through rows manually, IQD continuously scans incoming data to detect discrepancies. The system flags potential issues in real time, eliminating the need for periodic, human-led reviews. When discrepancies are found, IQD auto-generates suggested query texts. The data manager only reviews and approves or rejects the suggestions, and approved queries are automatically pushed into the EDC system. A further benefit is that IQD removes the need for listings altogether. Through natural language prompts, the algorithm adapts to each study’s requirements, eliminating manual configuration, while still supporting testing and validation. 

Cognivia | Cognivia Signal™ - Version 1 | Booth 33 
https://cognivia.com/cognivia-signal/ 

Clinical trials are plagued by high patient non-adherence and dropout rates—up to 40% of participants don’t follow medication protocols, and 30% drop out entirely. Each lost patient costs sponsors up to $19,500 or even more, causing significant delays, inflated budgets, and risking trial failure. These behavioral risks often go unnoticed until the damage is done. Cognivia Signal™ changes this dynamic. It’s the first real-time behavioral risk intelligence platform; it uses proprietary assessments and advanced machine learning to spot patients at risk of dropping out or failing to adhere—before they disrupt the trial. The platform delivers early warning indicators like declining motivation, mounting stress, or disengagement, allowing for swift, tailored interventions that keep patients enrolled and compliant. Cognivia Signal also benchmarks behavioral risks across sites and countries, equipping sponsors and CROs to allocate resources more effectively. It supports smarter, targeted patient and site training, and proactive management where it’s needed most. Crucially, it addresses placebo response risk by revealing behavioral drivers like patient expectations and other placebo response indicators at the site and country level. These insights enable sponsors to minimize “behavioral noise” and improve data reliability. Developed by Cognivia, a leader in behavioral analytics, Cognivia Signal gives clinical operations teams a brand-new visibility on major clinical trial risks. It transforms patient behavior from an unpredictable liability into a measurable, actionable signal- empowering sponsors to anticipate risk, intervene early, and protect trial integrity. 

Docuvera | Open Study Builder Integrator | Booth 43 
https://docuvera.com 

This solution solves the legacy issue of compliance and long cycle times for protocol approval and study start in clinical trials; reducing clinical study startup resource requirements and accelerating trial execution timelines. By adopting Digital Data Flow standards companies can move from a document-centric to a data-centric paradigm, enabling automation, interoperability, and reuse across the study lifecycle. The solution enables an end-to-end digital workflow integrating Open Study Builder (OSB) with Docuvera that automatically generates ICH M11-compliant protocols from CDISC USDM-structured study design; utilizes the TransCelerate Digital Data Flow technical frameworks for real-time integration between study design tools and protocol authoring systems; supports component-based authoring with automated FHIR export capabilities (enabling data-driven workflows); and generates the ICF from the Protocol (and other document types) using Docuvera GenAI. 

H1 | MyProjects | Booth 6 
https://h1.co/clinical/ 

Clinical research teams conducting trial feasibility studies and PI/site selection face significant organizational and collaboration challenges that impede efficient study startup. Traditional workflows force teams to work across disconnected systems and spreadsheets, making it difficult to maintain context around why specific investigators, sites, or patient populations were identified for potential trials. Research insights become scattered across individual files, email threads, and various platforms, creating knowledge silos that prevent effective collaboration. Teams struggle to maintain institutional memory about research decisions, site evaluation criteria, and investigator outreach strategies. Without proper collaborative platforms, teams resort to cumbersome email chains and version-controlled spreadsheets that quickly become outdated and difficult to navigate. These workflow inefficiencies directly impact study timeline planning and can delay critical trial startup activities, ultimately affecting patient access to investigational therapies. The clinical research industry needs centralized workspaces that preserve research context while enabling seamless collaboration throughout the feasibility and site selection process, allowing teams to leverage their data investments more effectively rather than constantly recreating institutional knowledge. That’s why we built MyProjects. 

Medidata | Medidata Protocol Optimization | Booth 26 
https://www.medidata.com/ 

Medidata’s innovative Protocol Optimization solution built on insights drawn from tens of thousands of historical clinical trials and 8000+ active studies worldwide, transforms trial design and execution by leveraging AI-driven capabilities to analyze study design and quantify the impact of protocol design decisions on operational outcomes like enrollment, retention, and cost. This solution can assess the impact on patient burden, site performance, and costs well in advance of the First Patient In (FPI), giving research and operations teams critical foresight into potential challenges. Protocol Optimization, launched in June 2025, begins with industry benchmarking, flagging commonly used procedures, synthesizing procedure frequency, and calculating the corresponding protocol complexity upfront. AI models use historical clinical trial data to simulate design trade-offs. The Patient Burden Index (PBI) incorporates many objective and subjective measures of the patient experience, including pain, hospitalization risk, procedure duration, and anxiety, enabling decisions to reduce patient burden without compromising endpoints. Predictive modeling then shows how protocol design changes are expected to impact burden and costs. This structured approach to protocol analysis significantly improves the protocol design process, decreases costly amendments, and informs enrollment planning, leading to smoother, lower-cost trials that are easier on patients and sites. 

Perceptive | ClinPhone Pro V1 | Booth 15 
https://www.perceptive.com/ 

ClinPhone Pro is a configurable solution designed for scalability and AI integration, enabling fast configuration and enhanced flexibility through self-service capabilities. Key features and functionality include flexibility and speed via self-service for immediate study changes, data access, and visualization, avoiding changes in scope and study delays. Users can activate new countries/regions, depots, and couriers; add or modify supply strategies (including all DNx settings); access and resend historic notifications and alerts; and tailor which notifications/alerts they wish to receive via email. Full lifecycle traceability means all activity is traced within the system via comprehensive, on-demand reports and an audit-trail log that can be filtered and exported as needed. It is designed for decentralized and hybrid trial models; core capabilities address direct-to-participant (DtP) and satellite site needs, with quick and efficient self-service tools to manage locally and centrally sourced materials and automatic supply-scheme switching. The platform offers a highly configurable dispensing design, allowing different quantities to be dispensed under different conditions. For automated restock of sites,  "one-click order" and “Forecast Order” tools simulate live supply scenarios, calculating projected needs for a site based on known and hypothetical variables. If a shipment is needed, the system offers immediate shipment-request creation, supporting enhanced planning, timely patient treatment, and reduced drug wastage, e.g. ensuring sites are supplied in advance of holidays when depots/couriers may shut down or operate with reduced capacity. For real-time study snapshots, dashboards provide participant recruitment progress, site and depot inventories, participant visit calendars, and a quick-view pane of unread notifications, with individual user notification management. 

Teckro  
Teckro | Booth 17 
http://teckro.com 

Teckro is a web- and mobile-based technology, accessed via a browser, mobile device or tablet. Available globally in all popular app stores, it is easy to access and use. Teckro is a digital platform revolutionizing clinical trial operations by enhancing site engagement and streamlining communication between sponsors, CRAs, and sites. Designed with a mobile-first approach, Teckro allows site staff to access study protocols, FAQs, and updates instantly from their devices, ensuring compliance and reducing delays. It also provides a seamless, real-time, in-app communication tool for sites to get faster answers to their study-specific questions. At its core, Teckro transforms static trial documents into dynamic, searchable content. This enables faster decision-making and improves protocol adherence. Sponsors benefit from real-time oversight of site performance, allowing them to identify high-performing locations and intervene where engagement is low. The platform’s intelligent analytics help optimize recruitment strategies, minimize compliance risk, and generally allow sponsors to achieve better outcomes with less burden on sites. Teckro also replaces outdated communication methods—like spreadsheets and email chains—with targeted, compliant messaging tools. This fosters better collaboration and ensures that critical updates reach the right people at the right time. 

WCG  
WCG Total Training | Booth 49 
https://www.wcgclinical.com/solutions/total-training/ 

WCG Total Training is the industry’s first end-to-end clinical trial training solution, purpose-built to unify live, virtual, hybrid, and on-demand training. The solution leverages advanced analytics, expert-led consulting, audience engagement tools, and intuitive technology, aimed at empowering research sites and sponsors with streamlined, efficient, and highly effective clinical trial training. Total Training’s impact is proven, delivering:  

• A 35–50% reduction in protocol deviations  

• 40% decrease in time from site initiation to first participant screened  

• 97% average content engagement rate among site staff  

• Support for 525,000 clinicians at 100,000 sites worldwide